Literature DB >> 1615580

Differential sensitivity of hormone-responsive and unresponsive human prostate cancer cells (LNCaP) to tumor necrosis factor.

X Zhao1, G J van Steenbrugge, F H Schröder.   

Abstract

Two sublines, the hormone-sensitive LNCaP-FGC and the insensitive LNCaP-r (resistant) carcinoma cell lines, originating from the parental human prostatic carcinoma cell line LNCaP were tested for sensitivity to human tumor necrosis factor-alpha (TNF) using the MTT assay. Irrespective of the culture conditions, i.e., whether FGC cell growth was hormone stimulated or hormone deprived, a clear dose-related response was observed between the concentration of TNF (range: 5-5000 U/ml) in the culture medium and the percentage of growth inhibition. In medium containing androgen-depleted serum, in which FGC cells showed reduced proliferative activity, the percentage of inhibition by a concentration of 100 U/ml TNF was substantially higher than that found in hormone-stimulated cells (90% and 60%, respectively). In contrast to the FGC cells, the hormone-insensitive LNCaP-r cells were almost completely resistant to the action of TNF. Growth of the FGC cells was almost completely inhibited, whereas growth of the LNCaP-r cells was retarded with only 20% at dosages up to 5000 U/ml. This substantial difference in TNF responsiveness could not be ascribed to differences in TNF-binding capacity, as both the FGC and LNCaP-r cells were found to contain identical numbers of TNF-receptors (approximately 1000 sites/cell). A possible association between hormone responsiveness and TNF sensitivity is suggested for these LNCaP sublines.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1615580     DOI: 10.1007/bf00299716

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  30 in total

1.  Antiproliferative and cytotoxic effects of single and combined treatment with tumor necrosis factor alpha and/or alpha interferon on a human renal cell carcinoma xenotransplanted into nu/nu mice: cell kinetic studies.

Authors:  H Baisch; U Otto; G Klöppel
Journal:  Cancer Res       Date:  1990-10-01       Impact factor: 12.701

2.  Physiologic basis for hormonal theapy in carcinoma of the prostate.

Authors:  P C Walsh
Journal:  Urol Clin North Am       Date:  1975-02       Impact factor: 2.241

3.  The LNCaP cell line--a new model for studies on human prostatic carcinoma.

Authors:  J S Horoszewicz; S S Leong; T M Chu; Z L Wajsman; M Friedman; L Papsidero; U Kim; L S Chai; S Kakati; S K Arya; A A Sandberg
Journal:  Prog Clin Biol Res       Date:  1980

4.  Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice.

Authors:  K Haranaka; N Satomi; A Sakurai
Journal:  Int J Cancer       Date:  1984-08-15       Impact factor: 7.396

Review 5.  Development of androgen-independent tumor cells and their implication for the treatment of prostatic cancer.

Authors:  J T Isaacs; N Kyprianou
Journal:  Urol Res       Date:  1987

Review 6.  The human prostatic cancer cell line LNCaP and its derived sublines: an in vitro model for the study of androgen sensitivity.

Authors:  G J van Steenbrugge; C J van Uffelen; J Bolt; F H Schröder
Journal:  J Steroid Biochem Mol Biol       Date:  1991       Impact factor: 4.292

7.  Differential sensitivity of renal cell carcinoma xenografts towards therapy with interferon-alpha, interferon-gamma, tumor necrosis factor and their combinations.

Authors:  A J Beniers; R J van Moorselaar; W P Peelen; F M Debruyne; J A Schalken
Journal:  Urol Res       Date:  1991

8.  Correlation between the anticellular and DNA fragmenting activities of tumor necrosis factor.

Authors:  B Y Rubin; L J Smith; G R Hellermann; R M Lunn; N K Richardson; S L Anderson
Journal:  Cancer Res       Date:  1988-11-01       Impact factor: 12.701

9.  Treatment of advanced prostatic carcinoma with estramustine phosphate (Estracyt).

Authors:  G Jönsson; B Högberg; T Nilsson
Journal:  Scand J Urol Nephrol       Date:  1977

10.  Growth inhibiting effect of estramustine on two prostatic carcinoma cell lines, LNCaP and LNCaP-r.

Authors:  M Hansenson; B Lundh; B Hartley-Asp; A Pousette
Journal:  Urol Res       Date:  1988
View more
  3 in total

1.  Reduced tumor necrosis factor receptor-associated death domain expression is associated with prostate cancer progression.

Authors:  Diping Wang; R Bruce Montgomery; Lucy J Schmidt; Elahe A Mostaghel; Haojie Huang; Peter S Nelson; Donald J Tindall
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

2.  Effect of tumor necrosis factor-alpha and interferon-gamma on the growth of human prostate cancer cell lines.

Authors:  Y Nakajima; A DelliPizzi; C Mallouh; N R Ferreri
Journal:  Urol Res       Date:  1995

3.  Proteomic comparison of prostate cancer cell lines LNCaP-FGC and LNCaP-r reveals heatshock protein 60 as a marker for prostate malignancy.

Authors:  Björn Johansson; Mohammad R Pourian; Yin-Choy Chuan; Irene Byman; Anders Bergh; See-Tong Pang; Gunnar Norstedt; Tomas Bergman; Ake Pousette
Journal:  Prostate       Date:  2006-09-01       Impact factor: 4.104

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.